Form 4: Evoke Pharma Director Benjamin C. Smeal Acquires Stock Options

Director Benjamin C. Smeal acquired stock options in Evoke Pharma, Inc. on October 18, 2024.

Summary

• On October 18, 2024, Benjamin C. Smeal, a director of Evoke Pharma Inc., acquired stock options.
• The stock options grant him the right to buy 5,833 shares of common stock at an exercise price of $5.51.
• The options vest in three equal installments annually, starting October 18, 2025, contingent upon continuous service to Evoke Pharma.
• Following the transaction, Smeal directly owns 5,833 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants. It doesn't inherently convey positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued service of the director to the company.

Industry Context

This is a standard regulatory filing related to insider transactions. It's common for directors and officers to receive stock options as part of their compensation packages, aligning their interests with the company's performance.

Stakeholder Impact

• The granting of stock options to a director can potentially align the director's interests with those of the shareholders, encouraging decisions that increase shareholder value.

Key Dates

Keywords

stock options, Form 4, Evoke Pharma, director, acquisition, Smeal, beneficial ownership